Idiopathic Pulmonary Fibrosis: Competitive Intelligence 2026

Cumberland Pharmaceuticals Inc. agreed to sell its branded pharmaceutical portfolio to Nuvo Pharmaceuticals (Ireland) DAC, an Apotex affiliate, for $100 million in cash, subject to shareholder approval.

IPF Relevance: Retained Pipeline

• Cumberland retains all pipeline product candidates, including ifetroban, which is in Phase II clinical programs for Idiopathic Pulmonary Fibrosis (IPF), Systemic Sclerosis (SSc), and Duchenne Muscular Dystrophy (DMD)
• Following the divestiture, ifetroban becomes Cumberland's primary remaining asset and development focus
• The $100 million in proceeds gives Cumberland a strengthened capital position from which to continue advancing ifetroban's clinical programs

Avalyn Pharma updated its IPO filing, announcing plans to raise approximately $283 million by offering 16.7 million shares at a price range of $16 to $18 per share. This represents a 41% increase in anticipated proceeds from the company's prior filing.

IPO Proceeds Allocation

• $150 million (plus existing cash and marketable securities) to advance AP01 (inhaled pirfenidone) through Phase 2b topline data and into Phase 3
• $90 million to progress AP02 (inhaled nintedanib) through an ongoing Phase 2 trial and into Phase 3
• $10 million to take AP03 (inhaled fixed-dose combination of pirfenidone and nintedanib) into Phase 1 clinical development

Capital Position

• Operations, including $15.0 million borrowed in February 2026 under a $30.0 million term loan facility, are estimated to be funded into 2029 with anticipated net IPO proceeds and existing capital
• As of December 31, 2025, Avalyn reported a net loss of $85.2 million and an accumulated deficit of $265.4 million

Rein Therapeutics, Inc. announced a public offering of 30,000,000 shares at an assumed price of $1.66 per share, targeting net proceeds of approximately $44.8 million for working capital and repayment of outstanding promissory notes.

Financial Position and Runway

• As of December 31, 2025: cash and cash equivalents approximately $3.2 million; working capital deficit approximately $1.9 million
• Proceeds combined with existing cash are expected to fund operations through at least April 2027

LTI-03: RENEW Phase 2 Clinical Trial

• LTI-03 is Rein's lead IPF product candidate, currently in the RENEW Phase 2 trial: multi-center, randomized, double-blind, placebo-controlled; approximately 120 IPF patients
• Patient recruitment resumed in the U.S. in February 2026 across approximately 20 U.S. sites, with approximately 30 additional sites in the UK, Germany, Poland, and Australia; first patient dosed March 2026
• Initial interim topline data expected Q4 2026
• Regulatory designations: FDA Orphan Drug, Rare Pediatric Disease, and Fast Track; EMA Orphan Drug designation (January 2026)

Baseimmune announced a strategic expansion into the fibrosis therapeutic area, with its lead program specifically targeting Idiopathic Pulmonary Fibrosis (IPF), leveraging its proprietary computational protein design platform.

Program Overview

• Baseimmune's approach is built around multi-pathway immune modulation, using advanced computational protein design to create antigens that influence interconnected pro-fibrotic signaling networks
• The strategy aims to interrupt and reset dysregulated pro-fibrotic circuits; the company views traditional single-target approaches as limited in fibrosis due to its complex and redundant biological pathways
• The IPF program is in preclinical development; key proof-of-concept efficacy readouts are anticipated in 2026 and 2027
• A Scientific Advisory Board (SAB) comprising experts in lung, liver, kidney, and heart fibrosis biology has been established to guide target strategy and early translational planning

Note: No asset name, mechanism of action, or financial terms were disclosed in the March 12, 2026 announcement.

Insilico Medicine announced its 2025 annual results, highlighting over 10 new collaborations totaling US$1.3 billion, with ISM001-055 (Rentosertib) identified as the company's lead clinical asset in IPF.

ISM001-055 (Rentosertib): IPF Clinical Program

• ISM001-055 is advancing in the Phase IIa GENESIS-IPF study for Idiopathic Pulmonary Fibrosis
• The GENESIS-IPF study demonstrated strong safety and tolerability with dose-dependent improvement in lung function; Insilico characterizes this as the first clinical proof-of-concept for an AI-discovered drug
• Complete study results published in Nature Medicine and presented at the 2025 American Thoracic Society (ATS) International Conference and Pulmonary Fibrosis Foundation (PFF) Summit
• An inhalable formulation of ISM001-055 has an IND application submitted for clinical trial, with potential advantages including a low efficacious dose, large safety window, and minimal side effects